Retatrutide
Key Takeaways: Retatrutide
Retatrutide is a GLP-1 peptide primarily researched for:
- Triple-agonist obesity-trial research interest
- Glycemic-control research interest
- Liver-fat reduction research interest
Research Profile
Retatrutide (LY3437943) is an experimental triple hormone receptor agonist (GLP-1, GIP, and glucagon) developed by Eli Lilly. It has generated strong obesity-trial interest, but cross-trial superlatives and storage assumptions should be made carefully.
Mechanism
By targeting three separate metabolic pathways simultaneously, Retatrutide combines GLP-1, GIP, and glucagon signaling. That triple-agonist profile distinguishes it mechanistically from dual agonists such as tirzepatide.
Research Findings
In Phase 2 trials, Retatrutide produced large weight-loss effects, including about 24.2% mean loss at the highest studied dose over 48 weeks. Those results should be tied to the trial population and dose rather than generalized beyond the study.
Use Retatrutide in the peptide calculator
This opens the current supported deep-link flow. Treat the preselected math as a starting point only, then adjust vial amount, reconstitution volume, and target amount to match your actual setup.
Use in CalculatorExpanded Research Context
Retatrutide in context: Retatrutide sits inside a family where the strongest public evidence usually comes from labeled metabolic products and large outcomes trials. That means the key reading task is separating what belongs to an approved formulation from what remains a research-vial handling assumption. This profile currently links 1 direct study reference, led by Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (2023).
What researchers usually look for on this page: The main research-interest signals surfaced here are Triple-agonist obesity-trial research interest, Glycemic-control research interest, Liver-fat reduction research interest. Those bullets should be read as topic clusters and literature themes, not as proof that every claimed effect is equally established across formulations, routes, or study populations.
Evidence ceiling: This page is currently best treated as moderate-confidence evidence with meaningful interpretation limits. The listed stability class is Standard, which helps with planning and internal consistency, but any duration or decay implication that is not directly tied to a label or linked paper should still be treated as conservative handling guidance rather than assay-proven shelf life.
Handling And Interpretation Notes
Reconstitution logic: Reconstitute with Bacteriostatic Water (1-2mL). Swirl gently; do not shake. In practical terms, that instruction should be read as a starting workflow rather than a universal protocol. When a page mentions a solvent or a mixing style, the stronger claim is usually about keeping concentration math and contamination control consistent, not about one magic solvent making the peptide stable by itself.
Cold-storage reading: Use conservative refrigerated handling; direct product-specific liquid shelf-life data remains limited Stable in fridge; degrades significantly (40%) in 30 days at room temp. PeptideClock treats post-reconstitution freezing as a high-risk event for this page unless formulation-specific evidence says otherwise.
Room-temperature caution: Avoid prolonged room-temperature exposure; storage assumptions should not be inferred directly from trial results Even when a peptide is described as more robust than average, that usually means “less fragile than peers,” not “immune to handling mistakes.” Repeated warm exposure, poor labeling, and uncertain contamination history can still make the vial a discard candidate before any visual defect appears.
Risk Framing And Next Questions
Tolerability language on this page: Nausea, Gastrointestinal discomfort, Increased heart rate (transient). These items are here to keep the page evidence-aware, especially where small studies, mechanistic papers, or legacy bioregulator literature might otherwise tempt broader safety conclusions than the sources support.
High-risk note: Retatrutide is flagged as a high-risk page in this repo, so readers should assume a lower tolerance for unsupported dosing, storage, or efficacy claims.
- Use the linked study section to anchor the strongest claim on the page before treating a benefit bullet as established.
- Use the calculator and storage tools for math and planning, not to upgrade weak evidence into stronger biological certainty.
- If a practical handling question depends on the exact formulation, route, or solvent, treat the answer as unresolved until the page links direct evidence for that exact setup.
What Raises Or Lowers Confidence
Confidence driver: This page has at least one direct study anchor, which is useful, but one citation rarely answers every practical handling question on its own.
What lowers confidence fastest: The biggest downgrade usually comes from mixing evidence types together. A page becomes easier to misread when label-backed facts, peer-reviewed findings, mechanism-only reasoning, and PeptideClock estimates are treated as interchangeable support.
What would strengthen this page: Direct formulation-matched stability studies, clearer route-specific data, and replicated human evidence would improve how much of the page can be read as established instead of provisional. The next useful question is usually whether a claim belongs to a labeled product, a compounding workflow, or a research-vial extrapolation.
- Prefer the linked study section over family-level reputation when weighing a specific benefit claim.
- Treat room-temperature and post-reconstitution handling as the least transferable claims unless directly studied.
- Use the confidence badge as a ceiling on certainty, not as a reason to ignore the page's stated limits.
Profile Reading Checklist
If you are using this profile to answer a practical research question, move through the page in order rather than jumping straight from the name to the calculator or the benefit list. That keeps the strongest evidence, the handling assumptions, and the model estimates in the correct order.
- Confirm whether the strongest claim you care about is supported by a linked study or only by family-level context.
- Match the storage and reconstitution notes to your exact material state: lyophilized powder, recently mixed vial, or repeatedly accessed solution.
- Separate biological interest from workflow certainty. A peptide can be interesting mechanistically while still having thin practical handling evidence.
- Use tools on the site for math and tracking only after deciding that the underlying evidence question has been framed correctly.
Evidence & Interpretation
What this page can support: 1 linked study on page, led by Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (2023).
Family context: For GLP-1 pages, the strongest claims usually come from labeled pharmaceutical products and large metabolic-outcomes trials. Storage windows and freeze guidance should stay tied to the exact formulation being discussed.
How to read the page: If you are looking at a reconstituted research preparation rather than an approved pen product, treat label-backed handling data as context, not automatic proof of equivalent stability.
Stability interpretation: Retatrutide is modeled as standard stability with medium confidence. Stable in fridge; degrades significantly (40%) in 30 days at room temp.
Freeze handling note: PeptideClock treats reconstituted material as a do-not-freeze case unless direct formulation evidence says otherwise.
Important limit: Any storage window, room-temperature note, or solvent implication on this page should be treated as formulation-specific evidence only when a linked study or product label directly supports it. Otherwise it is conservative handling guidance or a PeptideClock model-based planning aid.
Practical Research Planning
| Research question this page is best for | Mechanism, evidence strength, and conservative handling expectations for Retatrutide rather than treatment claims. |
|---|---|
| Best source type on page | Direct linked study or trial citation |
| Reconstitution takeaway | Reconstitute with Bacteriostatic Water (1-2mL). Swirl gently; do not shake. |
| Cold-storage takeaway | Use conservative refrigerated handling; direct product-specific liquid shelf-life data remains limited |
| Room-temperature caution | Avoid prolonged room-temperature exposure; storage assumptions should not be inferred directly from trial results |
How To Use This Profile
- Start with the study links and confidence badge before treating any benefit statement as settled.
- Use the storage and room-temperature notes as planning guidance, then verify whether your exact formulation matches the evidence source.
- Open the Potency Decay Calculator if you need a date-based estimate for this peptide's handling scenario.
- Read storage, dosing, or pharmacology claims alongside the site's research disclaimer, especially for high-risk or label-backed compounds.
Clinical Data & Studies
Evidence basis: The linked studies support the page's direct literature claims. They do not automatically validate every practical storage or dosing assumption for non-matching formulations.
Model note: When the calculator or stability copy goes beyond a direct study or label, PeptideClock treats those numbers as conservative planning estimates rather than assay-proven endpoints.
Related Reading & Tools
Open the current deep-link flow, then adjust the math for your own concentration and syringe-unit planning.
Review oxidation, temperature, and freeze-thaw context for peptide handling.
Check how PeptideClock distinguishes evidence, model estimates, and educational content.
Researched Effects
- Triple-agonist obesity-trial research interest
- Glycemic-control research interest
- Liver-fat reduction research interest
- Metabolic-outcomes trial interest
Potential Side Effects
- Nausea
- Gastrointestinal discomfort
- Increased heart rate (transient)
Stability Profile
Use conservative refrigerated handling; direct product-specific liquid shelf-life data remains limited
Avoid prolonged room-temperature exposure; storage assumptions should not be inferred directly from trial results
Related Peptides in GLP-1 Family
Liraglutide
Reconstitute with Bacteriostatic Water (typically pre-mixed pens).
Semaglutide
Approved products are supplied pre-formulated. Do not assume research-vial reconstitution behaves like labeled pen formulations.
Tirzepatide
Reconstitute with Bacteriostatic Water. Gentle swirl only.